| Identification | Back Directory | [Name]
Benzoic acid, 3-[[[[2-[(3R)-3-(2-ethoxyphenoxy)-1-piperidinyl]-5-pyrimidinyl]carbonyl]amino]methyl]- | [CAS]
1809064-23-0 | [Synonyms]
PF-06427878
(R)-3-((2-(3-(2-ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxamido)methyl)benzoic acid
Benzoic acid, 3-[[[[2-[(3R)-3-(2-ethoxyphenoxy)-1-piperidinyl]-5-pyrimidinyl]carbonyl]amino]methyl]- | [Molecular Formula]
C26H28N4O5 | [MOL File]
1809064-23-0.mol | [Molecular Weight]
476.52 |
| Chemical Properties | Back Directory | [density ]
1.281±0.06 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO: 2mg/mL, clear | [form ]
powder | [pka]
4.37±0.10(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Biological Activity]
PF-06427878 is an orally activepotent and selective diacylglycerol acyltransferase 2 inhibitor (human/r at DGAT2 IC50 = 99/202 nM; >470-fold selectivity over DGAT1MGAT1/2/3) th at inhibits DGAT2-dependent triglyceride (TG) synthesis in primary human hepatocytes (IC50 = 11.6 nM in the presence of DGAT1 inhibitor PF-04620110). PF-06427878 reduces hepatic and circulating plasma TG levels as well as lipogenic gene expression in rats maintained on a Western-type diet (0.3-30 mg/kg bid. po.). LikewisePF-06427878 significantly improves steatosis and hepatocellular ballooning with a decrease in lobular inflammation in a murine nonalcoholic steatohepatitis (NASH) model (2 or 20 mg/kg bid. po.). |
|
| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0150-83588313-811 18800520310 |
| Website: |
www.jiehuapharma.com/ |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|